Equities Analysts Issue Forecasts for Myomo FY2026 Earnings

Key Points

• HC Wainwright raised its Myomo earnings forecasts, projecting a FY2026 loss of $0.31 per share, versus its prior $0.32 estimate. It also sees losses narrowing in 2027 and forecasts profits of $0.20 per share in 2029 and $0.45 in 2030.
• Myomo’s latest reported quarter beat analyst expectations: its loss was $0.07 per share versus the $0.08 expected, while revenue of $12.33 million topped the $11.51 million estimate.
• Myomo shares opened at $1.25 and were down 1.6%; insiders had sold 47,738 shares worth about $70,662 over the preceding three months.

Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Myomo in a research note issued on Tuesday, November 10th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings of ($0.31) per share for the year, up from their prior forecast of ($0.32). The consensus estimate for Myomo's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Myomo's Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.12) EPS, FY2028 earnings at ($0.01) EPS, FY2029 earnings at $0.20 EPS and FY2030 earnings at $0.45 EPS.

Myomo Stock Down 1.6%

Shares of Myomo stock opened at $1.25 on Thursday. Myomo has a 1 year low of $0.60 and a 1 year high of $1.89. The company has a debt-to-equity ratio of 4.24, a current ratio of 1.92 and a quick ratio of 2.01. The stock has a 50-day moving average price of $1.37 and a 200 day moving average price of $1.09.

Myomo (NYSEAMERICAN:MYO - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $12.33 million during the quarter, compared to analyst estimates of $11.51 million. Myomo had a negative return on equity of 183.47% and a negative net margin of 33.14%.

Insider Buying and Selling at Myomo

In other news, insider Harry Kovelman sold 17,250 shares of the firm's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $1.73, for a total transaction of $29,842.50. Following the completion of the sale, the insider directly owned 105,983 shares of the company's stock, valued at $183,350.59. This trade represents a 14.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 47,738 shares of company stock worth $70,662. 12.14% of the stock is owned by company insiders.

Recent Myomo Headlines

Here are a few of the latest headlines about MYO:

• Positive Sentiment: HC Wainwright raised its estimates across 2026–2027, including its FY2027 loss forecast to $0.12 per share from $0.28. It also reduced projected quarterly losses for Q4 2026 and each quarter of 2027. Myomo analyst estimate updates
• Positive Sentiment: The analyst sees improving longer-term profitability, revising FY2028 to a loss of $0.01 per share from $0.18, FY2029 profit to $0.20 from $0.02, and FY2030 profit to $0.45 from $0.26. The upgrades suggest a faster path toward profitability, though those forecasts are several years out. Myomo analyst estimate updates
• Neutral Sentiment: A separate Q3 2026 earnings-call summary is listed, but the provided material contains only its headline and link, not enough detail to assess its implications. Myomo, Inc. Q3 2026 Earnings Call Summary

Myomo Company Profile

Myomo, Inc. is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user's residual muscle signals and assists movement of the arm and hand. The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.